According to research reviewed by Gram, dietary changes show the most promise for reducing lingering digestive symptoms in people with controlled inflammatory bowel disease, but the evidence remains very uncertain. A 2026 meta-analysis of 13 randomized trials involving 688 patients found that dietary interventions demonstrated the largest potential symptom benefit, though results varied widely between studies and study quality was often poor. Behavioral approaches like stress management showed smaller but more consistent benefits. Researchers conclude that larger, better-designed studies are needed before doctors can confidently recommend specific treatments for this common problem affecting about one-third of IBD patients in remission.
Many people with inflammatory bowel disease (IBD) continue to experience uncomfortable digestive symptoms even when their disease is under control. A Gram Research analysis of 13 clinical trials involving 688 patients found that dietary changes showed the most promise for reducing these lingering symptoms, though the evidence isn’t yet strong enough to make definitive recommendations. Behavioral approaches like stress management also helped somewhat. However, researchers say we need bigger, better-designed studies to figure out which treatments actually work best for this common problem that affects about one-third of IBD patients in remission.
Key Statistics
A 2026 meta-analysis of 13 randomized controlled trials involving 688 patients found that dietary interventions showed the largest potential benefit for reducing IBS-like symptoms in people with controlled inflammatory bowel disease, though evidence certainty was very low due to inconsistent results across studies.
According to the meta-analysis, behavioral interventions such as cognitive behavioral therapy and stress management demonstrated a small but consistent treatment effect for symptom relief in quiescent IBD patients with IBS-like symptoms, with low-certainty evidence.
More than half (53.8%) of the 13 trials included in the meta-analysis had high risk of bias, primarily due to lack of blinding and reliance on subjective symptom endpoints, limiting confidence in the overall findings.
Approximately one-third of patients with inflammatory bowel disease in remission experience persistent IBS-like symptoms that are not addressed by standard anti-inflammatory therapies, representing a significant unmet clinical need.
The Quick Take
- What they studied: Whether dietary changes, behavioral strategies, medications, or other treatments can reduce lingering digestive symptoms in people whose IBD is in remission (not actively flaring)
- Who participated: 688 adults across 13 different clinical trials who had inflammatory bowel disease that was controlled but still experienced irritable bowel syndrome-like symptoms such as cramping, bloating, and irregular bowel movements
- Key finding: Dietary interventions showed the largest potential benefit for symptom relief, but the evidence quality was very low due to inconsistent results across studies and small sample sizes in individual trials
- What it means for you: If you have IBD in remission but still have digestive symptoms, dietary changes may be worth exploring with your doctor, but don’t expect a guaranteed cure. More research is needed before doctors can confidently recommend specific dietary approaches. Work with your healthcare team to find what works for your body.
The Research Details
Researchers searched medical databases for all randomized controlled trials (the gold standard type of study) published through October 2025 that tested treatments for IBS-like symptoms in people with quiescent IBD. Quiescent means the disease is quiet or in remission, not actively causing inflammation. They found 13 trials that met their strict criteria and combined the results using statistical methods to see which types of treatments worked best.
The researchers organized the treatments into four categories: dietary interventions (like low-FODMAP diets or fiber changes), behavioral interventions (like cognitive behavioral therapy or stress management), medications, and other approaches. They measured two main outcomes: how much symptoms improved and how much quality of life improved.
They also carefully checked each study for potential problems, like whether patients knew which treatment they were getting (blinding is important because knowing you’re in a treatment group can affect results). They rated the overall certainty of evidence for each treatment type using a standard system called GRADE, which considers factors like study quality, consistency of results, and precision of findings.
This research approach matters because many IBD patients struggle with ongoing symptoms even when their disease is controlled by anti-inflammatory medications. These lingering symptoms significantly impact daily life, but doctors don’t have clear evidence about what treatments work best. By combining results from multiple trials, researchers can see the bigger picture and identify which approaches show the most promise, even if individual studies were too small to draw firm conclusions.
The study has both strengths and limitations. The strength is that it systematically reviewed all available randomized trials, which is the most rigorous way to combine evidence. However, the researchers found that more than half of the included studies had high risk of bias, meaning their results may not be fully reliable. The biggest problems were that many studies weren’t blinded (patients knew what treatment they were getting) and outcomes were subjective (based on what patients reported rather than objective measurements). The evidence for dietary interventions was rated very low certainty because results varied widely between studies and sample sizes were often small.
What the Results Show
Dietary interventions showed the largest potential benefit for reducing symptoms, with a standardized mean difference of -1.33. However, this result came with a very wide confidence interval (-4.42 to 1.77), meaning the true benefit could range from substantial improvement to actually making symptoms worse. The high variability between studies (measured as I-squared of 90%) indicates that different dietary approaches had very different results, so there’s no one-size-fits-all dietary solution.
Behavioral interventions, such as cognitive behavioral therapy and stress management programs, showed a small but more consistent benefit (standardized mean difference of -0.36) with low-certainty evidence. The results were more consistent across studies (I-squared of 0%), suggesting behavioral approaches work similarly across different populations, even if the benefit is modest.
For medications and other interventions, the evidence was too limited to draw any conclusions. Only a few small trials tested these approaches, so researchers couldn’t confidently say whether they work.
When looking at quality of life outcomes specifically, the patterns were similar to symptom outcomes, with dietary interventions showing the largest point estimates but with very uncertain evidence.
The analysis revealed that study quality significantly affected results. Studies with higher risk of bias tended to show larger treatment effects, suggesting that some of the apparent benefits may have been due to study design problems rather than true treatment effects. This finding highlights why the researchers emphasized the need for better-designed trials going forward. Additionally, the wide variation in dietary approaches tested (different types of diets, different durations, different populations) made it impossible to identify which specific dietary strategy works best.
This meta-analysis fills an important gap because most previous research on IBS-like symptoms in IBD focused on patients with active disease, not those in remission. The finding that current evidence doesn’t support any single definitive treatment aligns with the broader medical understanding that IBS-like symptoms in IBD are complex and likely multifactorial. The result also reflects a pattern seen in other areas of gastroenterology: dietary and behavioral interventions show promise but need more rigorous testing before they can be confidently recommended.
The main limitation is that the included studies were quite different from each other in terms of patient populations, specific interventions tested, and how outcomes were measured. This heterogeneity made it difficult to draw firm conclusions. Additionally, most studies had significant quality issues, particularly lack of blinding and reliance on subjective symptom reporting. The sample sizes in individual trials were often small, meaning results were imprecise. Finally, the meta-analysis only included published studies, so unpublished negative results may not have been captured, potentially making treatments appear more effective than they actually are.
The Bottom Line
Based on this research, dietary modifications may be worth exploring if you have IBD in remission with ongoing digestive symptoms, but discuss specific approaches with your gastroenterologist or dietitian first. Behavioral interventions like stress management or cognitive behavioral therapy show modest benefits and are generally safe to try. Confidence level: Low to very low for all recommendations, meaning we need more research before making strong claims. Work with your healthcare team to identify which approach might work for your individual situation, as responses vary widely between people.
This research is most relevant for people with IBD (Crohn’s disease or ulcerative colitis) whose disease is controlled but who continue to experience IBS-like symptoms. It’s also important for gastroenterologists and dietitians who treat these patients. People with IBS alone (without IBD) should not assume these findings apply to them, as the underlying biology is different. If you have active IBD inflammation, focus on controlling that first with your doctor before trying these symptom-management strategies.
If you try dietary or behavioral interventions, give them at least 4 to 8 weeks to show effects, as most studies measured outcomes at these timepoints. However, some people may notice changes sooner. Keep track of your symptoms during this period to see if you’re improving. If you don’t notice meaningful improvement after 8 to 12 weeks, discuss other options with your doctor.
Frequently Asked Questions
Can changing my diet help with IBS symptoms if I have IBD in remission?
Dietary changes show the most promise based on current research, but evidence is very uncertain. A 2026 meta-analysis found dietary interventions had the largest potential benefit, though results varied widely. Work with your gastroenterologist or dietitian to identify which specific dietary changes might help your individual situation.
What’s the difference between IBS-like symptoms and active IBD inflammation?
IBS-like symptoms include cramping, bloating, and irregular bowel movements without active inflammation. In remission, your IBD inflammation is controlled, but these symptoms persist. They’re harder to treat because anti-inflammatory medications don’t address them, requiring different management strategies.
Does stress management actually help with digestive symptoms in IBD?
Behavioral interventions including stress management showed a small but consistent benefit in the meta-analysis, with low-certainty evidence. While the improvement is modest, these approaches are generally safe and may be worth trying alongside other strategies recommended by your doctor.
How long should I try a new treatment before deciding if it works?
Most studies measured outcomes at 4 to 8 weeks, so give dietary or behavioral interventions at least this long to show effects. Track your symptoms during this period. If you don’t notice meaningful improvement after 8 to 12 weeks, discuss other options with your healthcare team.
Are medications effective for IBS-like symptoms in controlled IBD?
The meta-analysis found insufficient evidence to recommend any medications, as only isolated small trials tested pharmacologic approaches. Talk with your gastroenterologist about whether medication might be appropriate for your specific situation, as individual responses vary.
Want to Apply This Research?
- Log daily symptom severity (cramping, bloating, bowel movement frequency and consistency) on a scale of 0 to 10, along with what you ate and your stress level. Track this for 2 weeks before starting any intervention, then continue for 8 weeks during the intervention to see if patterns change.
- If trying dietary changes, start by eliminating one potential trigger food at a time for 2 weeks while tracking symptoms. If trying behavioral approaches, commit to one specific practice (like 10 minutes of daily meditation or a weekly therapy session) and log when you complete it. Use the app to set reminders and track consistency.
- Create a monthly symptom summary showing average severity scores and quality of life ratings. Compare month-to-month trends rather than day-to-day fluctuations, since digestive symptoms naturally vary. Share these summaries with your doctor at appointments to help guide treatment decisions.
This article summarizes research findings and should not replace professional medical advice. If you have inflammatory bowel disease or persistent digestive symptoms, consult your gastroenterologist before starting any new dietary, behavioral, or medical treatment. The evidence reviewed here is currently uncertain, and individual responses to treatments vary significantly. Your doctor can help determine which approaches are appropriate for your specific situation and monitor your progress.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.